J. Brayer

发表

Gastrointestinal absorption of insulin-like growth factor in the mouse in the absence of salivary insulin-like growth factor binding protein.

Y. Nakagawa, G. E. Oxford, K. Ishibashi, 1997, Biochemical pharmacology.

Expansion of Myeloid Suppressor Cells in SHIP-Deficient Mice Represses Allogeneic T Cell Responses1

C. Desponts, W. Kerr, J. Brayer, 2004, The Journal of Immunology.

Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjögren's syndrome.

R. Jonsson, C. Stewart, J. Brayer, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types

J. Machiels, F. Piette, K. Odunsi, 2017, BMJ Open.

WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides

J. Lancet, J. Pinilla-Ibarz, J. Brayer, 2015, American journal of hematology.

Enhancing synergy of CAR T cell therapy and oncolytic virus therapy for pancreatic cancer

Samuel H. Friedman, H. Enderling, J. Poleszczuk, 2016, bioRxiv.

Dynamic super-enhancer core regulatory circuits and epigenetic landscapes drive malignant progression and refractory disease in multiple myeloma

H. Dai, R. Gillies, R. Gatenby, 2021 .

A novel NOD-derived murine model of primary Sjögren's syndrome.

R. Jonsson, R. Holmdahl, J. Brayer, 1998, Arthritis and rheumatism.

Cell Responses SHIP-Deficient Mice Represses Allogeneic T Expansion of Myeloid Suppressor Cells in

W. Kerr, J. Brayer, E. Sotomayor, 2013 .

A Dual Role for Interferon‐γ in the Pathogenesis of Sjögren's Syndrome‐Like Autoimmune Exocrinopathy in the Nonobese Diabetic Mouse

J. Brayer, S. Cha, Juehua Gao, 2004, Scandinavian journal of immunology.

An Alternative Perspective to the Immune Response in Autoimmune Exocrinopathy: Induction of Functional Quiescence Rather Than Destructive Autoaggression

R. Jonsson, J. Brayer, M. Humphreys-Beher, 1999, Scandinavian journal of immunology.

Regression of metastatic clear cell kidney cancer with interleukin-2 treatment following nivolumab (anti-PD-1) treatment.

M. Fishman, J. Brayer, 2014, Journal of immunotherapy.

TLR5 ligation by flagellin converts tolerogenic dendritic cells into activating antigen-presenting cells that preferentially induce T-helper 1 responses.

J. Brayer, E. Sotomayor, F. Cheng, 2009, Immunology letters.

Aberrant proteolytic digestion of biglycan and decorin by saliva and exocrine gland lysates from the NOD mouse model for autoimmune exocrinopathy.

G. E. Oxford, J. Brayer, M. Humphreys-Beher, 2000, Clinical and experimental rheumatology.

NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient

S. Agaugué, J. Brayer, C. Lonez, 2018, Haematologica.

In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity.

A. Cuenca, Hong-wei Wang, J. Brayer, 2006, Blood.

Sjögren's syndrome: immunological response underlying the disease.

J. Brayer, M. Humphreys-Beher, A. Peck, 2001, Archivum immunologiae et therapiae experimentalis.

Transformation to Hodgkin lymphoma in chronic lymphocytic leukemia coexisting with Epstein–Barr viremia

J. Pinilla-Ibarz, J. Brayer, S. Dalia, 2014, Leukemia & lymphoma.

Differential absorption and distribution of epidermal growth factor and insulin-like growth factor in diabetic NOD mice.

G. E. Oxford, J. Brayer, M. Humphreys-Beher, 2001, Journal of diabetes and its complications.

Elevated proapoptotic Bax and caspase 3 activation in the NOD.scid model of Sjögren's syndrome.

J. Brayer, M. Humphreys-Beher, N. Talal, 2001, Arthritis and rheumatism.

Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3.

J. Pinilla-Ibarz, J. Brayer, Hongwei Wang, 2010, Immunology letters.

Evidence for antimuscarinic acetylcholine receptor antibody-mediated secretory dysfunction in nod mice.

J. Brayer, M. Humphreys-Beher, S. Cha, 2000, Arthritis and rheumatism.

Alleles from chromosomes 1 and 3 of NOD mice combine to influence Sjögren's syndrome-like autoimmune exocrinopathy.

J. Brayer, M. Humphreys-Beher, S. Cha, 2000, The Journal of rheumatology.

Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens.

A. Cuenca, H. Bien, J. Brayer, 2003, Cancer research.

The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma

J. Brayer, R. Baz, 2017, Therapeutic advances in hematology.

IL‐4‐Dependent Effector Phase in Autoimmune Exocrinopathy as Defined by the NOD.IL‐4‐Gene Knockout Mouse Model of Sjögren's Syndrome

J. Brayer, M. Humphreys-Beher, S. Cha, 2001, Scandinavian journal of immunology.

Excessive synthesis of matrix metalloproteinases in exocrine tissues of NOD mouse models for Sjögren's syndrome.

G. E. Oxford, J. Brayer, M. Humphreys-Beher, 1998, The Journal of rheumatology.

Connecting the Dots: A Case of Myeloid Sarcoma.

J. Brayer, A. Rose, 2018, The American journal of medicine.

Immunogenetics of autoimmune exocrinopathy in the nod mouse: more than meets the eye.

J. Brayer, M. Humphreys-Beher, S. Cha, 2000, Advances in experimental medicine and biology.

Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma

Christelle M Colin-Leitzinger, B. Sahaf, A. Mishra, 2022, Blood advances.

Abnormal Organogenesis in Salivary Gland Development May Initiate Adult Onset of Autoimmune Exocrinopathy

J. Brayer, M. Humphreys-Beher, M. Versnel, 2001, Experimental and Clinical Immunogenetics.

Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses

J. Brayer, J. Ochoa, S. Antonia, 2004, Cancer Research.

A critical role for Stat3 signaling in immune tolerance.

Hua Yu, Shizuo Akira, S. Akira, 2003, Immunity.

Developing strategies in the immunotherapy of leukemias.

J. Pinilla-Ibarz, J. Brayer, Javier Pinilla-Ibarz, 2013, Cancer control : journal of the Moffitt Cancer Center.

REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

S. Jagannath, M. Dhodapkar, G. Yancopoulos, 2020, Blood.

CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.

J. Machiels, A. Awada, J. Brayer, 2023, The Lancet. Haematology.

OMIP‐049: Analysis of Human Myelopoiesis and Myeloid Neoplasms

J. Mulé, J. Brayer, E. Padron, 2018, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Lenalidomide‐based response‐adapted therapy for older adults without high risk myeloma

B. Fridley, D. Sullivan, J. Brayer, 2018, British journal of haematology.

Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

Y. Houvras, S. Jagannath, J. Dey, 2022, Blood.

MM-087 Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma.

Y. Houvras, S. Jagannath, M. Dhodapkar, 2022, Clinical Lymphoma, Myeloma & Leukemia.

Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

S. Jagannath, M. Dhodapkar, A. Boyapati, 2021, Blood.

Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma

H. Dai, A. Silva, O. Hampton, 2021, JCI insight.

Pilot trial of a WT-1 analog peptide vaccine in patients with high-risk myeloid neoplasms.

J. Lancet, J. Pinilla-Ibarz, J. Brayer, 2014 .

High-Dimensional Flow Cytometry Analysis of Regulatory Receptors on Human T Cells, NK Cells, and NKT Cells.

J. Mulé, J. Brayer, A. Mailloux, 2020, Methods in molecular biology.

Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy

J. Brayer, Nathalie Braun, C. Lonez, 2018, Blood.

Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma

O. Hampton, Q. Mo, Mingxiang Teng, 2022, Blood advances.

Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study.

J. Brayer, K. Shain, F. Reu, 2022, Clinical lymphoma, myeloma & leukemia.

Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform

G. Morgan, J. Brayer, C. Lonez, 2021, Blood.

Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma

Abhishek Kumar, J. Brayer, F. Locke, 2023, Blood advances.

Clinical Development of a Non-Gene-Edited Allogeneic Bcma-Targeting CAR T-Cell Product in Relapsed or Refractory Multiple Myeloma

G. Morgan, L. Twyffels, J. Brayer, 2020 .

Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

K. Odunsi, A. Awada, J. Brayer, 2019, Blood.

The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

D. Sullivan, J. Brayer, Jongphil Kim, 2019, Blood.

NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient

S. Agaugué, J. Brayer, C. Lonez, 2018, Haematologica.